secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001193125-25-172653
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst expands Board to 7 with appointment of Dr. Daniel Curran
-----------------------------------------------------------------

- Board increased from 6 to 7 members; Dr. Curran appointed effective immediately.
- Curran brings 25+ years pharma experience; served as SVP at Takeda Rare Genetics (2019-2023).
- Currently CEO of Timberlyne Therapeutics and Managing Partner at Mountainfield Venture Partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/0001193125-25-172653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312525172653/d17349d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-172653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer